Optimizing Immunotherapy Sequencing in Gastroesophageal Malignancies: Neoadjuvant Chemo–IO vs Perioperative Chemo/RT Followed by Adjuvant Anti–PD-1

This discussion will compare strategies for sequencing immunotherapy in gastroesophageal malignancies, examining emerging clinical trial data, biologic rationale, and practical considerations influencing treatment selection. Faculty will address potential impacts on pathologic response, survival outcomes, and toxicity, as well as provide their expert perspectives on integrating immunotherapy across the perioperative continuum of care.